Complement Genomics

Executive Summary

Complement Genomics, founded in 2000 and headquartered in Lanchester, County Durham, UK, is a private DNA testing services company serving both businesses and the general public. The company offers a comprehensive range of genetic testing solutions, including human identity testing (e.g., paternity), animal and plant species identification, bird parentage and sexing, as well as support for human clinical trials. Their portfolio encompasses next-generation sequencing (NGS), Q-PCR, digital PCR, and biobanking services, positioning them as a versatile provider in the genomics space. With over two decades of operational history, Complement Genomics has established a reputation for reliability and technical expertise. The company holds particular expertise in pharmacogenetics, leveraging advanced genomic technologies to support personalized medicine initiatives. Their ability to integrate multiple testing modalities – from traditional PCR to high-throughput NGS – allows them to cater to diverse client needs across academic, clinical, and commercial sectors. While the genomics services market is competitive, Complement Genomics’ longevity and broad service range provide a stable foundation. Future growth may be driven by expanding pharmacogenetic offerings, forming strategic partnerships, or capitalizing on the increasing demand for precision medicine. However, the company operates as a private entity with limited public disclosure, making near-term catalysts uncertain. Overall, Complement Genomics represents a well-established, albeit lower-profile, player in the genetic testing industry.

Upcoming Catalysts (preview)

• TBDExpansion of pharmacogenetics testing menu with new NGS panels50% success